'Corrective genes' closer thanks to enzyme modification
Universite de Montreal - McGill University scientists detail modification of enzyme structure
Scientists from the Université de Montréal and McGill University have re-engineered a human enzyme, a protein that accelerates chemical reactions within the human body, to become highly resistant to harmful agents such as chemotherapy, according to a new study published in The Journal of Biological chemistry .
"Our team modified and decoded an enzyme structure," says Joelle Pelletier, a professor at the Université de Montréal's Department of Chemistry. "We discovered, to our surprise, that our intervention allowed the heart of the enzyme to increase its mobility. This unusual mobility caused the enzyme to resist the chemotherapy agent methotrexate – a result we never predicted and one that offers promise."
The research team made its discovery as it sought ways to help correct genetic diseases. "Our goal is to improve the injection of corrective genes in people suffering from genetic diseases," say Pelletier who is also co-director of PROTEO, a Quebec-based research group on the function, structure and engineering of proteins.
Original publication: Jordan P. Volpato, Elena Fossati Jonathan Blanchet, Lucie Poulin, Vanessa Guerrero, Joelle N. Pelletier, Brahm J. Yachnin and Albert M. Berghuis; "Multiple Conformers in Active Site of Human Dihydrofolate Reductase F31R/Q35E Double Mutant Suggest Structural Basis for Methotrexate Resistance"; The Journal of Biological Chemistry 2009.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
